HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Related Collections Related Article Social Bookmarking                What's this?

Prevention or Delay of Type 2 Diabetes

Abbreviations: CVD, cardiovascular disease • DPP, Diabetes Prevention Program • FPG, fasting plasma glucose • IFG, impaired fasting glucose • IGT, impaired glucose tolerance • NNT, number needed to treat • OGTT, oral glucose tolerance test • TRIPOD, Troglitazone in Prevention of Diabetes

The first 300 words of the full text of this article appear below.

	INTRODUCTION

 
Diabetes is one of the most costly and burdensome chronic diseases of our time and is a condition that is increasing in epidemic proportions in the U.S. and throughout the world (1). The complications resulting from the disease are a significant cause of morbidity and mortality and are associated with the damage or failure of various organs such as the eyes, kidneys, and nerves. Individuals with type 2 diabetes are also at a significantly higher risk for coronary heart disease, peripheral vascular disease, and stroke, and they have a greater likelihood of having hypertension, dyslipidemia, and obesity (2–6).

There is also growing evidence that at glucose levels above normal but below the diabetes threshold diagnostic now referred to as pre-diabetes, there is a substantially increased risk of cardiovascular disease (CVD) and death (5,7–10). In these individuals, CVD risk factors are also more prevalent (5–7,9,11–14), which further increases the risk but is not sufficient to totally explain it.

In contrast to the clear benefit of glucose lowering to prevent or retard the progression of microvascular complications associated with diabetes (15–18,21), it is less clear whether the high rate of CVD in people with impaired glucose homeostasis, i.e., those with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or diabetes, is caused by elevated blood glucose levels or will respond to treatments that lower blood glucose. Epidemiological studies have shown a clear relationship (19,20), whereas intervention trials in people with diabetes suggest, but have not demonstrated, a clear benefit of glycemic control (15,16,21,22). Additionally, there are no studies that have investigated a benefit of . . . [Full Text of this Article]

	QUESTION 1: Should we attempt to prevent diabetes?

 

	QUESTION 2: Who are potential candidates for screening and intervention?

 
Choice of screening test
Age considerations and screening frequency

	QUESTION 3: How should diabetes prevention be performed?

 
Lifestyle modification
Pharmacological interventions
Lifestyle or medication?

	QUESTION 4: How do strategies to prevent diabetes differ from those to treat diabetes?

 

	QUESTION 5: What additional research is needed?

 

	CONCLUSIONS

 

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article:

POSITION STATEMENTS & ADA STATEMENTS
Diabetes Care 2006 29: S75-S77. [Extract] [Full Text] [PDF]